Covered recipient · General Payments record
MICHAEL J OLIVER
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$387.82
28 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $387.82 | 28 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk Inc | $67.97 | 5 |
| AstraZeneca Pharmaceuticals LP | $52.31 | 4 |
| GlaxoSmithKline, LLC. | $49.26 | 3 |
| E.R. Squibb & Sons, L.L.C. | $38.87 | 3 |
| Amarin Pharma Inc. | $33.10 | 2 |
| PFIZER INC. | $25.89 | 2 |
| Janssen Pharmaceuticals, Inc | $24.53 | 2 |
| Corcept Therapeutics | $18.70 | 1 |
| Lilly USA, LLC | $16.47 | 1 |
| Astellas Pharma US Inc | $13.73 | 1 |
| Allergan, Inc. | $12.73 | 1 |
| Circassia Pharmaceuticals Inc | $11.72 | 1 |
| Merck Sharp & Dohme Corporation | $11.46 | 1 |
| Kowa Pharmaceuticals America, Inc. | $11.08 | 1 |
Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHAEL J OLIVER
NPI 1679501431 · CMS profile ID 121491
Allopathic & Osteopathic Physicians / Internal Medicine
BEAVER, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679501431?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679501431?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679501431?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1679501431?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
28 matching records · $387.82 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–28 of 28.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Allergan, Inc. | $12.73 | 12/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723348875 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.62 | 12/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736221477 | CMS |
| E.R. Squibb & Sons, L.L.C. | $11.84 | 11/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727958909 | CMS |
| PFIZER INC. | $13.33 | 11/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743797269 | CMS |
| PFIZER INC. | $12.56 | 11/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743797107 | CMS |
| Janssen Pharmaceuticals, Inc | $11.98 | 11/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719306253 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.15 | 11/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736328171 | CMS |
| Novo Nordisk Inc | $11.88 | 11/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745001169 | CMS |
| E.R. Squibb & Sons, L.L.C. | $12.81 | 10/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727958859 | CMS |
| Amarin Pharma Inc. | $20.39 | 10/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740079471 | CMS |
| Novo Nordisk Inc | $16.79 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744901413 | CMS |
| Corcept Therapeutics | $18.70 | 04/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744739871 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.97 | 03/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735823109 | CMS |
| Amarin Pharma Inc. | $12.71 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739984311 | CMS |
| GlaxoSmithKline, LLC. | $15.67 | 03/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738590667 | CMS |
| Janssen Pharmaceuticals, Inc | $12.55 | 02/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719306251 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.22 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727958763 | CMS |
| Kowa Pharmaceuticals America, Inc. | $11.08 | 02/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 716720323 | CMS |
| Merck Sharp & Dohme Corporation | $11.46 | 02/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747659023 | CMS |
| Novo Nordisk Inc | $12.65 | 02/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744585921 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.57 | 02/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735935024 | CMS |
| Novo Nordisk Inc | $14.02 | 02/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744723239 | CMS |
| Lilly USA, LLC | $16.47 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728569879 | CMS |
| Astellas Pharma US Inc | $13.73 | 01/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 718364081 | CMS |
| GlaxoSmithKline, LLC. | $17.20 | 01/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738764495 | CMS |
| GlaxoSmithKline, LLC. | $16.39 | 01/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738642983 | CMS |
| Novo Nordisk Inc | $12.63 | 01/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744559713 | CMS |
| Circassia Pharmaceuticals Inc | $11.72 | 01/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746985075 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,083,959.47 | 12 |
| PY2024 | Recipient | $43,914.50 | 5 |
| PY2024 | Principal investigator | $1,015,962.54 | 15 |
| PY2023 | Recipient | $195.00 | 1 |
| PY2023 | Principal investigator | $828,848.21 | 14 |
| PY2022 | Recipient | $34,661.00 | 4 |
| PY2022 | Principal investigator | $514,412.47 | 14 |
| PY2021 | Principal investigator | $507,716.92 | 33 |
| PY2020 | Recipient | $5,278.97 | 8 |
| PY2020 | Principal investigator | $291,944.00 | 17 |
| PY2019 | Recipient | $10,899.97 | 2 |
| PY2019 | Principal investigator | $442,530.95 | 27 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
15 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Eli Lilly and Company | $22,950.00 | 11/27/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1038149361 |
| Principal investigator 1 | Eli Lilly and Company | $3,018.56 | 10/01/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1038141459 |
| Principal investigator 1 | Eli Lilly and Company | $104,115.00 | 05/15/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1038155775 |
| Recipient | Eli Lilly and Company | $195.00 | 04/28/2023 | Covered Recipient Physician | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1038054013 |
| Principal investigator 1 | Eli Lilly and Company | $1,750.00 | 04/24/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1038151951 |
| Principal investigator 1 | Eli Lilly and Company | $3,750.00 | 04/10/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A RANDOMIZED PHASE 3 OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 1038146879 |
| Principal investigator 1 | Eli Lilly and Company | $4,560.82 | 02/21/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1038151939 |
| Principal investigator 1 | Eli Lilly and Company | $2,981.76 | 02/07/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS | No dispute reported | 06/30/2026 | 1038149899 |
| Principal investigator 1 | Eli Lilly and Company | $14,966.98 | 01/26/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1038151945 |
| Principal investigator 1 | Eli Lilly and Company | $313,439.00 | 01/13/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1038149879 |
| Principal investigator 1 | Eli Lilly and Company | $3,293.02 | 01/10/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1038149355 |
| Principal investigator 1 | Eli Lilly and Company | $45,661.10 | 01/04/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | No dispute reported | 06/30/2026 | 1038149893 |
| Principal investigator 1 | Eli Lilly and Company | $146,434.00 | 01/03/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS | No dispute reported | 06/30/2026 | 1038146887 |
| Principal investigator 1 | Eli Lilly and Company | $60,373.00 | 01/03/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1038149887 |
| Principal investigator 1 | Eli Lilly and Company | $101,554.97 | 01/03/2023 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | No dispute reported | 06/30/2026 | 1038155769 |